Abstract |
Tiapride, a selective D2 dopaminergic receptor blocking agent from the substituted benzamide class, was evaluated in a blind video-controlled trial in 10 psychiatric patients with tardive dyskinesia. There was a significant decrease in dyskinesia with a parallel increase in parkinsonism. This relationship between two opposite effects on movement suggests a common pathophysiological basis lying on a reciprocal hyper- and hypoactivity of the dopaminergic striatal system. Nevertheless, other mechanisms may be involved, for the evolution of individual parkinsonian and dyskinesia scores is not necessarily opposite: the tiapride-induced parkinsonism was generally acceptable and in two cases, the dyskinesia scores were reduced without an increase in parkinsonism. Therefore, more dyskinetic patients have to be evaluated in long-term studies with tiapride, before this drug could be recommended in tardive dyskinesia, when dyskinetic movements become intolerable.
|
Authors | P Pollak, J M Gaio, M Hommel, J Pellat, J Perret |
Journal | Psychopharmacology
(Psychopharmacology (Berl))
Vol. 85
Issue 2
Pg. 236-9
( 1985)
ISSN: 0033-3158 [Print] Germany |
PMID | 3925489
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Benzamides
- Tiapamil Hydrochloride
|
Topics |
- Adult
- Aged
- Benzamides
(therapeutic use)
- Clinical Trials as Topic
- Dyskinesia, Drug-Induced
(drug therapy)
- Female
- Humans
- Male
- Middle Aged
- Parkinson Disease, Secondary
(chemically induced)
- Tiapamil Hydrochloride
(adverse effects, therapeutic use)
|